Previous 10 | Next 10 |
home / stock / msclf / msclf news
Data support potential for SAT-3247 in multiple degenerative muscle diseases On track to initiate first-in-human clinical trial mid-2024 for Duchenne muscular dystrophy Satellos Bioscience Inc. (“Satellos” or the “Company”) (TSXV: MSCL) (OTCQB: ...
Satellos Bioscience Inc. (“Satellos” or the “Company”) (TSXV: MSCL) (OTCQB: MSCLF), a public biotech company developing new small molecule therapeutic approaches to improve the treatment of muscle diseases and disorders, announced today that Alan K. Jacobs, M.D., Chief...
Satellos Bioscience Inc. (“Satellos” or the “Company”) (TSXV: MSCL) (OTCQB: MSCLF), a public biotech company developing new small molecule therapeutic approaches to improve the treatment of muscle diseases and disorders, is pleased to announce that it has received cond...
2023-11-22 09:22:34 ET More on Satellos Bioscience Inc. Historical earnings data for Satellos Bioscience Inc. Financial information for Satellos Bioscience Inc. For further details see: Satellos Bioscience Inc. GAAP EPS of -C$0.03
Tekumo Inc (BCNN) is expected to report for Q3 2023 Diamcor Mining Inc (DMIFF) is expected to report for Q2 2024 American Bio Medica Corp. (ABMC) is expected to report for quarter end 2023-09-30 Northwest Biotherapeutics Inc (NWBO) is expected to report for Q1 2024 Inspired Entert...
iCo Therapeutics (MSCLF) is expected to report $-0.02 for Q3 2023
Satellos Bioscience Inc. (“Satellos” or the “Company”) (TSXV: MSCL) (OTCQB: MSCLF), a public biotech company developing new small molecule therapeutic approaches to improve the treatment of muscle diseases and disorders, announced today that management will present a...
The drug target for the Duchenne program is AAK1, a protein kinase in the Notch pathway, which the Company discovered can be modulated to enable muscle regeneration Satellos is conducting IND-enabling studies and GMP manufacturing, nominates SAT-3247 as lead drug candidate, files patent a...
Satellos Bioscience Inc. (“Satellos” or the “Company”) (TSXV: MSCL) (OTCQB: MSCLF), a public biotech company developing new small molecule therapeutic approaches to improve the treatment of muscle diseases and disorders, announced today that management will present a...
Toronto, Ontario--(Newsfile Corp. - September 20, 2023) - Satellos Bioscience Inc. (TSXV: MSCL) (OTCQB: MSCLF) ("Satellos" or the "Company"), a public biotech company developing new small molecule therapeutic approaches to improve the treatment of muscle diseases and disorders, announced today ...
News, Short Squeeze, Breakout and More Instantly...
iCo Therapeutics Company Name:
MSCLF Stock Symbol:
OTCMKTS Market:
Satellos Bioscience Inc. (TSX: MSCL, OTCQB: MSCLF) (“ Satellos ” or the “ Company ”), a public biotech company developing new small molecule therapeutic approaches to improve the treatment of muscle diseases and disorders, announced today the results of...
- Conducted preclinical toxicology studies and GMP manufacturing of SAT-3247 - On track to initiate Phase 1 first-in-human clinical trials mid-2024 - Cash balance of $33.2 million at March 31, 2024 - Invited to present at PPMD 30 th annual conference to be held J...
Satellos Bioscience Inc. (“Satellos” or the “Company”) (TSX: MSCL) (OTCQB: MSCLF), a public biotech company developing new small molecule therapeutic approaches to improve the treatment of muscle diseases and disorders, announced today that management will present at...